November 7,CARGENE BIOPHARMAAnnounce,Recently, at the event hosted by the American Association for the Study of Liver Diseases (AASLD)CARGENE BIOPHARMA proudly presented its globally pioneering liver regeneration candidate drug LR1 at the annual liver disease conference.At this highly anticipated annual meeting, CARGENE BIOPHARMACARGENE BIOPHARMA to Present Two Key Reports:
- On November 11, Dr. Chen Sihui, Vice President of Biology at CARGENE BIOPHARMA, will present a speech titled "LR1: A Promoter for LiverZang RegenerationReport on "A Novel siRNA Drug for Protecting Liver Function";
- On November 13, Dr. Torsten Wuestefeld, founder and advisor of CARGENE BIOPHARMA, willOral presentation on the Quartz platform, a groundbreaking in vivo target discovery platform targeting liver diseases.Platform.
As the world's first siRNA drug promoting liver regeneration, LR1 provides hope for cirrhosis patients at risk of liver failure.Provided a completely new mechanism and innovative solution, which has already demonstrated its ability to maintain and improve in preclinical animal models.The potential of liver function fills a significant gap in the treatment of liver diseases. Preclinical data presented by Dr. Chen Sihui highlights this advancement.In addition to LR1's ability to promote liver regeneration, it can also prevent further deterioration of a functionally declining liver, thereby avoiding liver damage.Ultimately losing the ability to compensate for liver function or even complete failure.More than 2 million people die each year from cirrhosis caused by chronic liver disease, making liver failure due to cirrhosis a leading cause of death globally.One of the chronic diseases with the highest mortality rate. The existing treatment method - liver transplantation, has serious limitations, makingPatients and doctors are anxiously awaiting more universally effective therapies. Globally, there are over 100 million patients with liver cirrhosis, andDue to the sharp increase in patients with non-alcoholic steatohepatitis (NASH), the number of cirrhosis patients is still rising rapidly.This calls for a breakthrough solution.CARGENE BIOPHARMA CEO Heidi H. Qi-Zhi expressed anticipation for LR1's therapeutic potential: "By leveraging the liver's inherent regenerative capabilities...The ability to treat liver diseases has long been a wish for liver disease researchers, and there is a huge unmet need in this field.Request. By combining the advantages of siRNA with our first-in-class liver regeneration target, LR1 has tremendous potential to improveEnhance the self-regeneration and repair capabilities of patients with advanced cirrhosis, completely transforming the treatment困境 where transplantation is the only option.Environment.”CARGENE BIOPHARMA sincerely invites AASLD annual meeting attendees to listen to Dr. Chen Sihui's presentation on November 11 about"LR1: A Novel siRNA Drug Promoting Liver Regeneration and Protecting Liver Function" will be presented at the conference.Preclinical research data of LR1. In addition, Dr. Torsten Wuestefeld will present on Quartz on November 13.Oral report in Taiwan, the Quartz platform is the engine for CARGENE BIOPHARMA to discover innovative targets and will continue to generate a seriesList innovative targets and pipelines.CARGENE BIOPHARMA is a global biotechnology company focused on developing innovative therapies for liver diseases.With the help of the Quartz in vivo target discovery platform developed by Dr. Torsten Wuestefeld, CARGENE BIOPHARMA advances its research on novel targets.An in-depth understanding of points combined with extensive industry experience in nucleic acid drug chemistry addresses diseases with highly unmet needs.Develop novel siRNA drugs.Copyright © 2023 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprinting, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
PharmaCube Reader Survey Questionnaire
Thank You for Your Company, Looking Forward to Your Feedback
Scan the QR code to provide valuable suggestions
